104 related articles for article (PubMed ID: 11959885)
1. On the eve of protein destruction: ubiquitin research begins to pay off.
Garber K
J Natl Cancer Inst; 2002 Apr; 94(8):550-2. PubMed ID: 11959885
[No Abstract] [Full Text] [Related]
2. Oncogenic aberrations of cullin-dependent ubiquitin ligases.
Guardavaccaro D; Pagano M
Oncogene; 2004 Mar; 23(11):2037-49. PubMed ID: 15021891
[TBL] [Abstract][Full Text] [Related]
3. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.
Burger AM; Seth AK
Eur J Cancer; 2004 Oct; 40(15):2217-29. PubMed ID: 15454246
[TBL] [Abstract][Full Text] [Related]
4. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
Allende-Vega N; Saville MK
Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
[TBL] [Abstract][Full Text] [Related]
5. Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
Lamsoul I; Uttenweiler-Joseph S; Moog-Lutz C; Lutz PG
Biochimie; 2016 Mar; 122():339-47. PubMed ID: 26253693
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of ubiquitin ligases in cancer.
Qi J; Ronai ZA
Drug Resist Updat; 2015 Nov; 23():1-11. PubMed ID: 26690337
[TBL] [Abstract][Full Text] [Related]
7. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
8. Could combinations of new and old drugs enhance tumor cell death?
Delou JM; Hajdu KL; Borges HL
Future Oncol; 2018 Oct; 14(23):2319-2322. PubMed ID: 30139272
[No Abstract] [Full Text] [Related]
9. BMS and Exelixis target tumor suppression pathways.
Expert Rev Anticancer Ther; 2001 Aug; 1(2):167. PubMed ID: 12113021
[No Abstract] [Full Text] [Related]
10. Ubiquitin ligases and cell cycle control.
Teixeira LK; Reed SI
Annu Rev Biochem; 2013; 82():387-414. PubMed ID: 23495935
[TBL] [Abstract][Full Text] [Related]
11. The marriage of growth factor inhibitors and chemotherapy: bliss or bust?
Staal S; O'Connell MJ; Allegra CJ
J Clin Oncol; 2009 Apr; 27(10):1545-8. PubMed ID: 19224842
[No Abstract] [Full Text] [Related]
12. Early stopping of trials.
Hopf G
Lancet; 1997 Sep; 350(9081):891. PubMed ID: 9310635
[No Abstract] [Full Text] [Related]
13. Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways?
Lecker SH
Curr Opin Clin Nutr Metab Care; 2003 May; 6(3):271-5. PubMed ID: 12690258
[TBL] [Abstract][Full Text] [Related]
14. Approval may embolden industry to combine cancer therapies.
Deng B
Nat Med; 2015 Feb; 21(2):105. PubMed ID: 25654594
[No Abstract] [Full Text] [Related]
15. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
16. Drug targeting in cancer therapy: the magic bullet, what next?
Duncan R; Connors TA; Meada H
J Drug Target; 1996; 3(5):317-9. PubMed ID: 8866651
[No Abstract] [Full Text] [Related]
17. The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy.
Motegi A; Murakawa Y; Takeda S
Cancer Lett; 2009 Sep; 283(1):1-9. PubMed ID: 19201084
[TBL] [Abstract][Full Text] [Related]
18. [The tumor suppressor HACE1 targets Rac1 to ubiquitin-mediated proteasomal degradation].
Gacon G; Mettouchi A; Lemichez E
Med Sci (Paris); 2012 Jan; 28(1):39-41. PubMed ID: 22289828
[No Abstract] [Full Text] [Related]
19. TRIM proteins and diseases.
Watanabe M; Hatakeyama S
J Biochem; 2017 Feb; 161(2):135-144. PubMed ID: 28069866
[TBL] [Abstract][Full Text] [Related]
20. Emerging roles of ubiquitin in transcription regulation.
Conaway RC; Brower CS; Conaway JW
Science; 2002 May; 296(5571):1254-8. PubMed ID: 12016299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
